{
    "nctId": "NCT04234620",
    "briefTitle": "Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .",
    "officialTitle": "A Prospective, Single-arm, Multicenter, Non-interventional Real-world Study of Toripalimab Injection in the Treatment of Malignant Tumors in Chinese Population.",
    "overallStatus": "UNKNOWN",
    "conditions": "Melanoma, Lung Cance, Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 800,
    "primaryOutcomeMeasure": "The incidence of all ADR.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients with approved indications of Toripalimab injection;\n2. Patients treated with Toripalimab injection;\n3. Patients who agreed to participate in this study and signed an informed consent form.\n\nExclusion Criteria:\n\n1. Refused to participate or refused to cooperate with the procedure;\n2. Those who participated in the intervention study of other unapproved drugs / therapies and less than 5 half-lives after the last use of the study drugs.",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}